HRP20211005T1 - Postupci i pripravci za stimuliranje crijevnog enteroendokrinog sustava u svrhu liječenja bolesti ili patoloških stanja u svezi toga - Google Patents
Postupci i pripravci za stimuliranje crijevnog enteroendokrinog sustava u svrhu liječenja bolesti ili patoloških stanja u svezi toga Download PDFInfo
- Publication number
- HRP20211005T1 HRP20211005T1 HRP20211005TT HRP20211005T HRP20211005T1 HR P20211005 T1 HRP20211005 T1 HR P20211005T1 HR P20211005T T HRP20211005T T HR P20211005TT HR P20211005 T HRP20211005 T HR P20211005T HR P20211005 T1 HRP20211005 T1 HR P20211005T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- aminosterol
- disease
- medications
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 14
- 238000000034 method Methods 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 3
- 230000000968 intestinal effect Effects 0.000 title claims 2
- 230000000638 stimulation Effects 0.000 title claims 2
- 201000010099 disease Diseases 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 51
- 229940079593 drug Drugs 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 24
- 208000024891 symptom Diseases 0.000 claims 20
- 238000002483 medication Methods 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 13
- 208000023105 Huntington disease Diseases 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 230000018109 developmental process Effects 0.000 claims 9
- 229940088597 hormone Drugs 0.000 claims 8
- 239000005556 hormone Substances 0.000 claims 8
- 230000000324 neuroprotective effect Effects 0.000 claims 8
- 108090000189 Neuropeptides Proteins 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 206010008129 cerebral palsy Diseases 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010003805 Autism Diseases 0.000 claims 3
- 208000020706 Autistic disease Diseases 0.000 claims 3
- 206010039966 Senile dementia Diseases 0.000 claims 3
- 230000008901 benefit Effects 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 230000008569 process Effects 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229940125681 anticonvulsant agent Drugs 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000008736 traumatic injury Effects 0.000 claims 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims 1
- SGEIEGAXKLMUIZ-ZPTIMJQQSA-N (3e)-n-[(2r)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride Chemical compound C([C@H](O)CN1CCCCC1)O\N=C(\Cl)C1=CC=C[N+]([O-])=C1 SGEIEGAXKLMUIZ-ZPTIMJQQSA-N 0.000 claims 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 229960000571 acetazolamide Drugs 0.000 claims 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 229940124604 anti-psychotic medication Drugs 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229950011582 arimoclomol Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960002161 brivaracetam Drugs 0.000 claims 1
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims 1
- 229960001403 clobazam Drugs 0.000 claims 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 1
- 229960003120 clonazepam Drugs 0.000 claims 1
- 229960004362 clorazepate Drugs 0.000 claims 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 229940110767 coenzyme Q10 Drugs 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 230000003131 corticotrophic effect Effects 0.000 claims 1
- FASDKYOPVNHBLU-SSDOTTSWSA-N dexpramipexole Chemical compound C1[C@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-SSDOTTSWSA-N 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- 229960003529 diazepam Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 1
- 229960002767 ethosuximide Drugs 0.000 claims 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 1
- 229960003472 felbamate Drugs 0.000 claims 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims 1
- 229960000693 fosphenytoin Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003871 intestinal function Effects 0.000 claims 1
- 229960002623 lacosamide Drugs 0.000 claims 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229960003587 lisuride Drugs 0.000 claims 1
- 229960004391 lorazepam Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960003793 midazolam Drugs 0.000 claims 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims 1
- 229960001165 modafinil Drugs 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- -1 olezoxime Chemical compound 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 claims 1
- 229960003868 paraldehyde Drugs 0.000 claims 1
- 229960001412 pentobarbital Drugs 0.000 claims 1
- 229960004851 pergolide Drugs 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 229960002695 phenobarbital Drugs 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 229960004310 piribedil Drugs 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960002393 primidone Drugs 0.000 claims 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 229960003312 retigabine Drugs 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 208000026451 salivation Diseases 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 229950000852 seletracetam Drugs 0.000 claims 1
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 229950001248 squalamine Drugs 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229950004608 talampanel Drugs 0.000 claims 1
- 229960005333 tetrabenazine Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims 1
- 229960001918 tiagabine Drugs 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- WUJVPODXELZABP-FWJXURDUSA-N trodusquemine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCNCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 WUJVPODXELZABP-FWJXURDUSA-N 0.000 claims 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims 1
- 229960005318 vigabatrin Drugs 0.000 claims 1
- 229960002911 zonisamide Drugs 0.000 claims 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (28)
1. Pripravak, naznačen time, da sadrži farmaceutski prihvatljiv stupanj kakvoće najmanje jednog aminosterola, ili njegove farmaceutski prihvatljive soli, za uporabu u liječenju ili prevenciji stanja ili poremećaja koji imaju blagodati od stimulacije GI odgovora induciranog aminosterolom kod pojedinca, i time, da se stanje ili poremećaj odnosi na živčani sustav i može imati koristi od neurozaštite, pri čemu:
(a) uporaba obuhvaća oralno davanje pripravka; i
(b) najmanje jedan aminosterol, ili njegova farmaceutski prihvatljiva sol, nalazi se u pripravku u dozi koja je dovoljna za proizvodnju korisnog neurozaštitnog učinka kod pojedinca;
(c) aminosterol je skvalamin ili njegova sol ili aminosterol 1436 ili njegova sol; i
(d) stanje ili poremećaj koji se odnosi na živčani sustav je Parkinsonova bolest, Alzheimerova bolest, Huntingtonova bolest, amiotrofična lateralna skleroza, akutna traumatska ozljeda središnjeg živčanog sustava, moždani udar, povreda kralježnice, degenerativni procesi povezani sa starenjem, staračka demencija, cerebralna palsija, epilepsija, periferna senzorna neuropatija, depresija, ili autizam.
2. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest Parkinsonova bolest.
3. Pripravak za uporabu prema patentnom zahtjevu 2, naznačen time, da pripravak ostvaruje poboljšanu svrhu crijeva kod pojedinaca.
4. Pripravak za uporabu prema patentnom zahtjevu 2 ili 3, naznačen time, da:
(a) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje Parkinsonove bolesti ili pripadajućih simptoma; ili
(b) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje Parkinsonove bolesti ili pripadajućih simptoma i jedan ili više medikamenata biraju se iz skupine koju čine levodopa, inhibitor dopa dekarboksilaze, COMT-inhibitor, agonisti dopamina, inhibitori MAO-B, karbidopa, beserazid, tolkapon, entakapon, bromokriptin, pergolid, pramipeksol, ropinirol, piribedil, kabergolin, apomorfin, lizurid, rotigotin, selegilin, rasagilin, amantadin, antikolinergici, klozapin, inhibitori kolinesteraze i modafinil.
5. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 2 do 4, naznačen time, da pripravak rezultira u:
(a) aktiviranju proizvodnje neuroprotektivnih hormona ili neuropeptida, što ima za svrhu da sprečava početak ili razvoj Parkinsonove bolesti ili pripadajućih simptoma; i/ili
(b) sprečavanju akumulacije alfa sinukleina, čime se sprečava početak ili razvoj Parkinsonove bolesti ili pripadajućih simptoma.
6. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest Alzheimerova bolest.
7. Pripravak za uporabu prema patentnom zahtjevu 6, naznačen time, da pripravak aminosterola:
(a) aktivira proizvodnju neuroprotektivnih hormona ili neuropeptida u mozgu, što ima za svrhu da sprečava početak ili razvoj Alzheimerove bolesti ili pripadajućih simptoma; i/ili
(b) fizički smanjuje koncentraciju beta-amiloida povezanih s membranom na njihovim ciljanim membranama, čime se svrhovito sprečava početak ili razvoj Alzheimerove bolesti ili pripadajućih simptoma.
8. Pripravak za uporabu prema patentnom zahtjevu 6 ili 7, naznačen time, da:
(a) pripravak aminosterola se daje zajedno ili u kombinaciji s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje Alzheimerove bolesti ili pripadajućih simptoma; ili
(b) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje Alzheimerove bolesti ili pripadajućih simptoma i jedan ili više medikamenata biraju se iz skupine koju čine glutamat, antipsihotički lijekovi, huperzin A, inhibitori acetilkolinesteraze, antagonist receptora NMDA, memantin, donepezil, galantamin i rivastigmin.
9. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest Huntingtonova bolest i/ili Huntingtonova koreja.
10. Pripravak za uporabu prema patentnom zahtjevu 9, naznačen time, da pripravak aminosterola aktivira proizvodnju neuroprotektivnih hormona ili neuropeptida u mozgu, koji imaju svrhu da sprečavaju početak ili razvoj Huntingtonove bolesti i/ili Huntingtonove koreje ili pripadajućih simptoma.
11. Pripravak za uporabu prema patentnom zahtjevu 9 ili 10, naznačen time, da:
(a) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje Huntingtonove bolesti i/ili Huntingtonove koreje ili pripadajućih simptoma; ili
(b) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje Huntingtonove bolesti i/ili Huntingtonove koreje ili pripadajućih simptoma i jedan ili više medikamenata biraju se iz skupine koju čine antipsihotički lijekovi, medikamenti koji se koriste za liječenje distonije, medikamenti koji reguliraju GABA, regulatori dopamina, antikonvulzanti, lijekovi koji se koriste za liječenje depresije i preostali medikamenti koji se uobičajeno koriste za liječenje Huntingtonove bolesti kao što su amantadin, tetrabenazin, blokatori dopamina i koenzim Q10.
12. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest amiotrofična lateralna skleroza.
13. Pripravak za uporabu prema patentnom zahtjevu 12, naznačen time, da pripravak aminosterola aktivira proizvodnju neuroprotektivnih hormona ili neuropeptida u mozgu, što ima za svrhu da sprečava početak ili razvoj amiotrofične lateralne skleroze ili pripadajućih simptoma.
14. Pripravak za uporabu prema patentnom zahtjevu 12 ili 13, naznačen time, da:
(a) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje amiotrofične lateralne skleroze ili pripadajućih simptoma; ili
(b) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje amiotrofične lateralne skleroze ili pripadajućih simptoma i jedan ili više medikamenata biraju se iz skupine koju čine riluzol, KNS-760704, olezoksim, talampanel, arimoklomol, i medikamenti koji pomažu u smanjivanju umora, olakšavanju grčeva u mišićima, kontroli spasticiteta, smanjivanju prekomjernog lučenja sline i flegmatičnosti, suzbijanju bolova, depresije, uznemirenosti kod spavanja, disfagije i konstipacije.
15. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj je traumatska povreda središnjeg živčanog sustava, moždani udar, povreda kralježnice ili periferna senzorna neuropatija.
16. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jesu degenerativni procesi povezani sa starenjem ili staračka demencija.
17. Pripravak za uporabu prema patentnom zahtjevu 16, naznačen time, da pripravak aminosterola aktivira proizvodnju neuroprotektivnih hormona ili neuropeptida u mozgu, što ima za svrhu da sprečava početak ili razvoj degenerativnih procesa koji su povezani sa starenjem ili staračke demencije ili pripadajućih simptoma.
18. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest cerebralna palsija.
19. Pripravak za uporabu prema patentnom zahtjevu 18, naznačen time, da pripravak aminosterola aktivira proizvodnju neuroprotektivnih hormona ili neuropeptida u mozgu, što ima za svrhu da sprečava početak ili razvoj cerebralne palsije ili pripadajućih simptoma.
20. Pripravak za uporabu prema patentnom zahtjevu 19, naznačen time, da se pripravak aminosterola daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje cerebralne palsije ili pripadajućih simptoma, kao što su injekcije botulinum toksin A.
21. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest depresija.
22. Pripravak za uporabu prema patentnom zahtjevu 21, naznačen time, da:
(a) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje depresije; ili
(b) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje depresije i jedan ili više medikamenata biraju se iz skupine koju čine triciklički antidepresivi, inhibitori monoaminske oksidaze, selektivni inhibitori preuzimanja serotonina, i inhibitori preuzimanja serotonina i norepinefrina.
23. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest epilepsija.
24. Pripravak za uporabu prema patentnom zahtjevu 23, naznačen time, da:
(a) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje epilepsije ili pripadajućih simptoma; ili
(b) pripravak aminosterola se daje zajedno ili kombinira s jednim ili više medikamenata koji se uobičajeno propisuju za liječenje epilepsije ili pripadajućih simptoma i jedan ili više medikamenata biraju se iz skupine koju čine antikonvulzanti, klorazepat, klonazepam, etosuksimid, felbamat, fosfenitoin, gabapentin, lakozamid, lamotrigin, levetiracetam, okskarbazepin, fenobarbital, fenitoin, pregabalin, primidon, tiagabin, topiramat, valproat seminatrij, valproična kiselina, i zonisamid, klobazam, vigabatrin, retigabin, brivaracetam, seletracetam, diazepam, lorazepam, paraldehid, midazolam, pentobarbital, acetazolamid, progesteron, adenokortikotropni hormoni, različiti kortikotropni steroidni hormoni i bromid.
25. Pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da stanje ili poremećaj jest autizam.
26. Pripravak za uporabu prema patentnom zahtjevu 25, naznačen time, da pripravak aminosterola aktivira proizvodnju neuroprotektivnih hormona ili neuropeptida u mozgu, što ima za svrhu da sprečava početak ili razvoj autizma ili pripadajućih simptoma.
27. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 26, naznačen time, da:
(a) učinkovita dnevna količina doze iznosi oko 0,1 do oko 20 mg/kg tjelesne mase; i/ili
(b) učinkovita doza se utvrđuje putem definiranja inicijalne doze koja je potrebna da inducira GI odgovor induciran aminosterolom, pri čemu se kod inicijalne doze radi o potrebnoj dozi za stimulaciju promjene kod crijevne aktivnosti, povraćanja, sekretne dijareje ili bilo koje njihove kombinacije.
28. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 27, naznačen time, da:
(a) pripravak se nalazi u obliku oralne doze koja je tekućina, kapsula, ili tableta oblikovana da se dezintegrira u želucu, gornjem malom crijevu, ili u udaljenijim dijelovima crijevnog sustava, s brzinom otapanja koja je prikladna za postizanje namijenjene terapijske koristi; i/ili
(b) pripravak nadalje sadrži najmanje jedan farmaceutski prihvatljiv nosač.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015657P | 2014-06-23 | 2014-06-23 | |
| US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| PCT/US2015/036935 WO2015200195A1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| EP15811714.3A EP3157531B1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211005T1 true HRP20211005T1 (hr) | 2021-09-17 |
Family
ID=54869043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211005TT HRP20211005T1 (hr) | 2014-06-23 | 2021-06-24 | Postupci i pripravci za stimuliranje crijevnog enteroendokrinog sustava u svrhu liječenja bolesti ili patoloških stanja u svezi toga |
Country Status (18)
| Country | Link |
|---|---|
| US (10) | US10040817B2 (hr) |
| EP (1) | EP3157531B1 (hr) |
| JP (2) | JP6692300B2 (hr) |
| CN (2) | CN106535902B (hr) |
| BR (1) | BR112016029917A2 (hr) |
| CA (1) | CA2951720C (hr) |
| CY (1) | CY1124554T1 (hr) |
| DK (1) | DK3157531T3 (hr) |
| ES (1) | ES2878077T3 (hr) |
| HR (1) | HRP20211005T1 (hr) |
| HU (1) | HUE054828T2 (hr) |
| LT (1) | LT3157531T (hr) |
| MX (2) | MX2016017368A (hr) |
| PL (1) | PL3157531T3 (hr) |
| PT (1) | PT3157531T (hr) |
| RS (1) | RS62064B1 (hr) |
| SI (1) | SI3157531T1 (hr) |
| WO (1) | WO2015200195A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| US20180344748A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating chronic inflammatory diseases |
| EP3678671A4 (en) * | 2017-09-08 | 2022-12-07 | Enterin, Inc. | METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS |
| MA50536A (fr) | 2017-10-30 | 2020-09-09 | Enterin Inc | Nouvelles formes solides de squalamine et procédés pour les produire |
| KR20200146038A (ko) * | 2018-03-27 | 2020-12-31 | 엔테린, 인코포레이티드 | 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물 |
| MX2020013614A (es) * | 2018-06-13 | 2021-05-27 | Enterin Inc | Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad. |
| US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
| US20210260078A1 (en) * | 2018-08-03 | 2021-08-26 | Philadelphia | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
| EP4007581A4 (en) * | 2019-08-02 | 2023-10-25 | Enterin, Inc. | DOSAGE PROTOCOLS AND REGIMES FOR AMINOSTEROL TREATMENT |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
| ES2123133T3 (es) | 1993-03-10 | 1999-01-01 | Magainin Pharma | Derivados esteroidianos, composiciones farmaceuticas que contienen estos derivados esteroidianos y utilizacion de estos ultimos como antibioticos o desinfectantes. |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| AU3512595A (en) | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
| US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| EP0832094B1 (en) | 1995-06-07 | 2004-02-11 | Genaera Corporation | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
| US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
| US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
| PT910382E (pt) | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| EP0923377A1 (en) | 1996-05-17 | 1999-06-23 | Magainin Pharmaceuticals Inc. | Therapeutic uses for an aminosterol compound |
| WO1998019682A1 (en) | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
| AU773038B2 (en) | 1998-08-12 | 2004-05-13 | Genaera Corporation | Aminosterol compounds and uses thereof |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| US7144877B2 (en) * | 2000-10-06 | 2006-12-05 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| KR20100056569A (ko) * | 2002-01-28 | 2010-05-27 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료 방법 |
| AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| JP2008539243A (ja) | 2005-04-25 | 2008-11-13 | ジェネーラ・コーポレーション | スクアラミンジラクテートの多形塩形態および無定形塩形態 |
| CA2697744C (en) | 2007-09-06 | 2016-06-14 | Genaera Corporation | A method for treating diabetes |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| US8729058B2 (en) | 2009-10-27 | 2014-05-20 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| KR101963312B1 (ko) | 2012-04-20 | 2019-03-28 | 오에이치알 파마서티컬, 인코포레이티드 | Ptp1b 연관 질병의 치료용 아미노스테로이드 |
| CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
| JP6434916B2 (ja) | 2012-12-20 | 2018-12-05 | マウント デザート アイランド バイオロジカル ラボラトリー | 組織の再生の刺激および促進 |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 MX MX2016017368A patent/MX2016017368A/es unknown
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en active Application Filing
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-24 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211005T1 (hr) | Postupci i pripravci za stimuliranje crijevnog enteroendokrinog sustava u svrhu liječenja bolesti ili patoloških stanja u svezi toga | |
| Li et al. | Review of pharmacological treatment in mood disorders and future directions for drug development | |
| Lew | Overview of Parkinson's disease | |
| Ravindran et al. | Pharmacotherapy of PTSD: premises, principles, and priorities | |
| Rezak | Current pharmacotherapeutic treatment options in Parkinson’s disease | |
| AU2007235517B2 (en) | Use of rasagiline for the treatment of Restless Legs Syndrome | |
| Hashimoto | The role of glutamate on the action of antidepressants | |
| Li et al. | Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test | |
| Shimazaki et al. | Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test | |
| DeMaagd et al. | Parkinson’s disease and its management: part 4: treatment of motor complications | |
| Devos et al. | New pharmacological options for treating advanced Parkinson’s disease | |
| Vlaar et al. | The treatment of early Parkinson's disease: levodopa rehabilitated | |
| WO2011143721A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| Staud | Pharmacological treatment of fibromyalgia syndrome: new developments | |
| Jones et al. | Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition | |
| Owolabi et al. | Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test | |
| Spaeth et al. | Fibromyalgia: a complex syndrome requiring a multidisciplinary approach | |
| Contreras-Mora et al. | Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): implications for treating motivational dysfunctions | |
| Prica et al. | Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? | |
| Törnblom et al. | Centrally targeted pharmacotherapy for chronic abdominal pain: understanding and management | |
| Nimah et al. | Tramadol-associated mania: A case report | |
| Alizadeh et al. | Effects of treadmill exercise on methadone withdrawal-induced locomotor sensitization and the ventral pallidum and ventral tegmental area BDNF levels in morphine withdrawn rats receiving methadone maintenance treatment | |
| Venkatesh et al. | Antidepressant like Effect of Gabapentin Decreases the Immobility Time in Despair Animal Models in Mice: Roll of Serotonergic System in it. | |
| Srinivasan et al. | Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment | |
| Ergün et al. | Combination therapy of imipramine and melatonin: additive antidepressant effect in mouse forced swimming test |